Madras HC: Police Superintendent not Liable For IO’s Delay In Filing Chargesheet or Closure Report  ||  Supreme Court: Provident Fund Dues Have Priority over a Bank’s Claim under the SARFAESI Act  ||  SC Holds Landowners Who Accept Compensation Settlements Cannot Later Seek Statutory Benefits  ||  Supreme Court: Endless Investigations and Long Delays in Chargesheets Can Justify Quashing  ||  Delhi HC: Arbitrator Controls Evidence and Appellate Courts Cannot Reassess Facts  ||  Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint  ||  Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint  ||  Delhi HC: Economic Offender Cannot Seek Travel Abroad For Medical Treatment When Available In India  ||  SC: Governors and President Have No Fixed Timeline To Assent To Bills; “Deemed Assent” is Invalid  ||  SC: Assigning a Decree For Specific Performance of a Sale Agreement Does Not Require Registration    

Indian Patent Office Disallows Patent for Boehringer Ingelheim’s HIV Drug, Nevirapine - (21 Oct 2015)

Indian Patent Office has disallowed Germany's Boehringer Ingelheim a patent on its HIV drug, Nevirapine, sold as Viramune XR (extended release), yet again thwarting attempts by Big Pharma for "exclusivity" extension on their patented drugs to reportedly block entry of affordable generics.

Tags : BOEHRINGER INGELHEIM   PATENT   HIV DRUG   NEVIRAPINE  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved